Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2018-03-05 Share Issue/Capital Cha…
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Informations mensuelles relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223- 16 du règlement général de l'Autorité des marchés financiers" (Monthly information relating to the total number of voting rights and shares provided for by Article L. 233-8 II of the Commercial Code and Article 223-16 of the General Regulation of the Financial Markets Authority). This structure, providing a monthly update on the total number of shares and voting rights as mandated by French financial regulations (AMF), strongly aligns with the definition of a regulatory filing that reports on share structure changes or related metrics, but it is not a standard US SEC filing like 10-K or a general earnings release. Given the specific nature of reporting voting rights and share counts monthly, it fits best under the general regulatory announcement category, which is RNS, or potentially a specific category if one existed for voting rights. Since there is no specific 'Voting Rights Update' code, and it is a mandatory regulatory disclosure, RNS (Regulatory Filings) is the most appropriate fallback, although it is highly specific. However, upon reviewing the definitions, none perfectly match a mandatory monthly voting rights disclosure from a French company. The closest related concept is DVA (Declaration of Voting Results & Voting Rights Announcements), but DVA is defined as 'Official results from shareholder votes at any general meeting (AGM or EGM)'. This document is a *monthly count*, not the *results of a vote*. Therefore, RNS (Regulatory Filings) serves as the best general regulatory disclosure category.
2018-03-05 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is a short, formal notification from bioMérieux, dated February 6, 2018, detailing the total number of shares and voting rights as of January 31, 2018. It explicitly references Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des marchés financiers (AMF). This type of mandatory monthly disclosure regarding share capital and voting rights is a specific regulatory filing requirement in France. While it contains financial/share data, it is not a comprehensive report (like 10-K or IR). It most closely aligns with a specific regulatory disclosure. Given the options, 'Regulatory Filings' (RNS) is the most appropriate general category for mandatory, periodic regulatory updates that don't fit a more specific financial report type, although it is highly specific in nature. However, since the content is purely about the number of shares and voting rights, and there is no specific code for 'Share Capital/Voting Rights Update', RNS serves as the best fit among the provided choices for a mandatory regulatory disclosure.
2018-02-06 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Regulatory Filings Classification · 99% confidence The document is dated January 8, 2018, and explicitly titled 'Bilan semestriel du contrat de liquidité de la société bioMérieux' (Semi-annual balance sheet of the bioMérieux liquidity contract). It details the holdings (shares and cash) in the liquidity account as of December 31, 2017, compared to the previous semi-annual balance (June 30, 2017). This type of regular update concerning market making or liquidity provision contracts is a specific financial disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR). It most closely aligns with a specialized financial disclosure related to market operations, which fits best under Regulatory Filings (RNS) as a specific, non-core report, or potentially a specialized financial notice. Given the options, RNS is the most appropriate fallback for a specific, non-standard financial disclosure like a liquidity contract balance sheet update, although it is highly specific. However, since the content is purely about the status of a liquidity contract (a form of market stabilization/support), and it is a periodic report, it is a specific financial disclosure. Since there is no specific code for 'Liquidity Contract Update', RNS (Regulatory Filings) is the best fit as a miscellaneous regulatory disclosure.
2018-01-08 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Regulatory Filings Classification · 95% confidence The document is a short filing from bioMérieux, dated January 5, 2018, detailing the total number of shares and voting rights as of December 31, 2017. The title explicitly references Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation, which mandates monthly disclosure of total voting rights and shares. This type of mandatory periodic disclosure regarding share capital structure and voting rights, especially when presented in a tabular format for a specific cutoff date, aligns best with general regulatory reporting requirements. Since there is no specific code for 'Monthly Voting Rights Report' and it is not a full financial report (10-K, IR), nor a director's dealing (DIRS), the most appropriate general category for mandatory regulatory updates on share structure is 'Regulatory Filings' (RNS). It is too specific for a general 'Share Issue/Capital Change' (SHA) as it focuses purely on voting rights count, not a transaction announcement.
2018-01-05 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Regulatory Filings Classification · 95% confidence The document is a short filing from bioMérieux, dated December 5, 2017, detailing the total number of shares and voting rights as of November 30, 2017. It explicitly references Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF (Autorité des marchés financiers) General Regulation. This structure is characteristic of mandatory monthly disclosures regarding share capital and voting rights, which often fall under general regulatory announcements or specific capital change notifications. Given the options, this is a specific regulatory disclosure concerning share structure and voting rights, but it does not fit perfectly into the defined categories like DIRS (Director's Dealing) or SHA (Share Issue/Capital Change, which usually implies a new issuance). However, the content is a formal regulatory update on the capital structure's voting power. Since it is a mandatory disclosure related to share capital structure and voting rights, and not a general announcement of a report (RPA/RNS), it is best classified as a specific regulatory filing. In the context of the provided definitions, it is a formal regulatory filing that doesn't match the other specific codes well, but it is highly specific to share structure. Since it is a formal, periodic disclosure mandated by financial regulators (AMF), and it deals with the total number of voting rights, it is a type of regulatory filing. Given the options, and noting that it is a formal disclosure of share structure information, it is closest to a general Regulatory Filing (RNS) or potentially a Share Issue/Capital Change (SHA) if interpreted broadly, but RNS is the safest fallback for specific, non-standard regulatory updates. Upon re-evaluation, this specific type of monthly voting rights disclosure is often categorized under general regulatory announcements when a more precise code isn't available. I will use RNS as the general regulatory filing category.
2017-12-05 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Regulatory Filings Classification · 95% confidence The document is titled 'Informations mensuelles relatives au nombre total de droits de vote et d'actions' (Monthly information relating to the total number of voting rights and shares) and references French regulatory articles (Article L. 233-8 II of the Commercial Code and Article 223-16 of the AMF General Regulation). It presents a table showing the total number of shares and voting rights as of a specific date (31/10/2017). This structure strongly indicates a mandatory disclosure regarding share capital and voting rights, which is typically covered under general regulatory filings or specific share/capital change notifications. Given the options, this is a specific regulatory disclosure about the capital structure and voting rights, which is often reported via general regulatory channels. Since there isn't a specific code for 'Voting Rights Disclosure' outside of DVA (which is for voting *results*), and it's not a full report (10-K, IR), the most appropriate general regulatory category is RNS, or potentially SHA if focusing strictly on capital structure changes, but RNS is the best fit for mandatory, periodic regulatory updates that don't fit other specific financial report types. However, upon reviewing the definitions, this specific type of disclosure (monthly voting rights/share count) is a common regulatory filing. Since it is a direct disclosure of share count and voting rights, it aligns closely with the spirit of 'Share Issue/Capital Change' (SHA) or a general 'Regulatory Filing' (RNS). Given the context of mandatory disclosure under AMF rules, RNS is the safest general classification for non-standard reports. If we strictly interpret the content as a notification about the current state of shares and voting rights, RNS (Regulatory Filings) is the most appropriate fallback for mandatory disclosures not covered elsewhere.
2017-11-06 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.